Avecho’s licensing deal with Sandoz has been picked up by...

Avecho’s licensing deal with Sandoz has been picked up by numerous pharma specialist sites and overseas news agencies, including in Europe and Asia. Below is a sample.

https://biopharmaboardroom.com/news...ustralian-rights-to-cbd-insomnia-capsule.html

https://www.thepharmaletter.com/pharmaceutical/avecho-and-sandoz-sign-exclusive-deal-in-australia

https://firstwordpharma.com/story/5939458

https://pharmadispatch.com/news/san...icinal-cannabis-company-in-ten-year-agreement

https://cannabislicenseexperts.com/...o commercialise CBD for insomnia in Australia

https://biopharmaapac.com/news/30/6...-pharmaceutical-cbd-capsule-for-insomnia.html

https://www.biospectrumasia.com/new...-cbd-for-insomnia-treatment-in-australia.html

https://www.medindia.net/health-pre...se-cbd-for-insomnia-in-australia-706117-1.htm

https://afndaily.com/avecho-biotechnology标志与sandoz进行cbd失眠治疗的独家许可协议/

https://www.prnewswire.co.uk/news-r...-cbd-for-insomnia-in-australia-302390766.html

https://www.fuw.ch/sandoz-erwirbt-kommerzielle-rechte-an-cannabidiolkapsel-von-avecho-599260393526

https://www.finanzen.ch/nachrichten...g-mit-avecho-umsatz-und-gewinnplus-1034439605

https://fr.finance.yahoo.com/actual...Bk2luqDrB6zokklwxWp97V9oNe3vReuOwywInhdgpyYBG

https://www.lelezard.com/communique-21728321.html

https://www.bolsamania.com/nota-de-...usivo-de-licencia-y-desarrollo--19091803.html

https://www.europapress.es/comunica...usivo-licencia-desarrollo-20250304172840.html

https://www.pointofnews.it/ultime_notizie_su_avecho

https://www.ceskenoviny.cz/zpravy/a.../2642719?utm_source=rsspr&utm_medium=feed

https://www.prnewswire.com/news-releases/avecho--sandoz-----------------302392401.html

https://www.prnewswire.com/news-rel...ro-lebu-nespavosti-v-australii-302392043.html

CEO Paul Gavin has also been interviewed by 180 Markets (see video below). Some new insights provided in this interview include:

There are many companies interested in licensing in other territories and there certainly has been an increased interest in entering discussions since the Sandoz deal was announced earlier this week.

The rapid onset gummies which the company has developed have been the subject of long discussions for use in the recreational space in the United States and Canada. These discussions have taken the back seat over the past 4-5 months while focus has been on Sandoz. Those discussions will now be given more focus. In addition, there have been “lots of interested parties” in the opportunity of medicinal gummies in Australia.

Currently building a roadshow, especially for Europe, which is the world’s largest medicinal cannabis market. Germany is of particular interest as it is the world’s largest national medicinal cannabis market. The company is also “very interested” in Japan, which has recently changed rules to allow acceptance of clinical trial data generated in other countries. Brazil, Israel and South Africa were also mentioned as potential targets.